Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Blood (2024) 144 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2024-210451

Published: 2024

Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study

Enrique M Ocio, Aurore Perrot, Pierre Bories, Jesús F. San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Song-Yau Wang, Sara Bringhen, Maria-Victoria Mateos, Paula Rodríguez-Otero, Stefania Oliva, Axel Nogai, Bruno Paiva, Yi Li, Eric Le Bras, Sandrine Macé, Ercem Kodas, Helgi Van de Velde, Philippe Moreau

Blood (2024) 144 (Supplement 1): 1976.

https://doi.org/10.1182/blood-2024-200135

Published: 2024

Journal Articles

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Blood (2023) 142 (Supplement 1): 782.

https://doi.org/10.1182/blood-2023-178835

Published: 2023

Journal Articles

Real-World Analysis of Teclistamab in 115 RRMM Patients from Germany

Blood (2023) 142 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2023-180032

Published: 2023

Journal Articles

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, Regina Herbst, Friedrich Stoelzel, Christoph Röllig, Edgar Jost, Richard F. Schlenk, Richard Noppeney, Christian H. Brandts, Utz Krug, Katharina S. Goetze, Sebastian Buske, Axel Florschütz, Jörg Schubert, Bernhard Opitz, Martin Mohren, Eva Eßeling, Stephan von Witzendorff, Marion Subklewe, Martin Kaufmann, Norbert Frickhofen, Christian W Scholz, Kerstin Schäfer-Eckart, Volker Kunzmann, Martin Schmidt-Hieber, Herbert G. Sayer, Andreas Rank, Philipp Hemmati, Frank Schueler, Simone Kowoll, Marina Scheller, Jörg Steighardt, Bayram Edemir, Lutz Peter Mueller, Irit Gliko-Kabir, Beatrice Ludwig-Kraus, Sabine Edemir, Ella Sorani, Mascha Binder, Abi Vainstein, Shaul Kadosh, Cora Gromann, Andreas Wienke, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhaeuser, Christian Junghanss, Carsten Mueller-Tidow

Blood (2022) 140 (Supplement 1): 3338–3340.

https://doi.org/10.1182/blood-2022-166748

Published: 2022

Journal Articles

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Blood (2022) 140 (Supplement 1): 1836–1838.

https://doi.org/10.1182/blood-2022-156309

Published: 2022

Journal Articles

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Blood (2018) 132 (Supplement 1): 253.

https://doi.org/10.1182/blood-2018-99-111203

Published: 2018

Journal Articles

Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma

Blood (2018) 132 (Supplement 1): 254.

https://doi.org/10.1182/blood-2018-99-119762

Published: 2018

Journal Articles

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Enrique M. Ocio, MD, Paula Rodriguez Otero, MD, Sara Bringhen, MD, Stefania Oliva, Axel Nogai, MD, Michel Attal, MD PhD, Philippe Moreau, Dheepak Kanagavel, Thomas F Fitzmaurice, PhD, Junlong Wu, Joaquin Martinez Lopez, MD PhD

Blood (2018) 132 (Supplement 1): 595.

https://doi.org/10.1182/blood-2018-99-111244

Published: 2018

Journal Articles

Quantitative Detection of DNMT3A R882H Mutation in Course of Treatment of Acute Myeloid Leukemia Patients

Olga Blau, MD PhD, Rimma Berenstein, Claudia Baldus, MD PhD, Nikola Suckert, Kathrin Rieger, MD, Axel Nogai, MD, Antonio Pezzutto, MD PhD, Bernd Doerken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2015) 126 (23): 4970.

https://doi.org/10.1182/blood.V126.23.4970.4970

Published: 2015

Journal Articles

SIRT3 Modulates Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells of Multiple Myeloma Patients

Rimma Berenstein, Igor Wolfgang Blau, MD PhD, Axel Nogai, MD, Marlies Waechter, Martin Schmidt-Hieber, MD PhD, Antonio Pezzutto, MD PhD, Bernd Doerken, MD PhD, Olga Blau, MD PhD

Blood (2015) 126 (23): 5325.

https://doi.org/10.1182/blood.V126.23.5325.5325

Published: 2015

Journal Articles

Cyclin D1 C.870G>a Polymorphism in Patients with Multiple Myeloma after Allogeneic Stem Cells Transplantation

Olga Blau, MD PhD, Ekaterina Slonova, Rimma Berenstein, Axel Nogai, MD, Kathrin Rieger, MD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2014) 124 (21): 2576.

https://doi.org/10.1182/blood.V124.21.2576.2576

Published: 2014

Journal Articles

Multiple Myeloma Cells Induce Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells

Rimma Berenstein, Olga Blau, MD PhD, Axel Nogai, MD, Marlies Wächter, Martin Schmidt-Hieber, MD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2014) 124 (21): 3357.

https://doi.org/10.1182/blood.V124.21.3357.3357

Published: 2014

Journal Articles

Aberrant Expression Of miRNA and mRNA Of Cell Cycle and Adhesion-Related Genes In Bone Marrow Stroma Cells Derived From Patients With Multiple Myeloma

Rimma Berenstein, Blau Igor Wolfgang, MD, PhD, Axel Nogai, MD, Marlies Wächter, Antonio Pezzutto, MD, PhD, Bernd Dörken, MD, PhD, Olga Blau, MD, PhD

Blood (2013) 122 (21): 3149.

https://doi.org/10.1182/blood.V122.21.3149.3149

Published: 2013

Journal Articles

Successful Treatment of High-Risk and Refractory Acute Myeloid Leukemia with haploidentical Stem Cell Transplantation Plus NK cell therapy

Lutz Uharek, MD, Birte Friedrichs, MD, Axel Nogai, MD, Chiara Gentilini, MD, Nadezda Basara, MD, Dietger Niederwieser, MD, Eckhard Thiel, MD

Blood (2010) 116 (21): 2370.

https://doi.org/10.1182/blood.V116.21.2370.2370

Published: 2010

Journal Articles

Organ Siderosis In a Murine Graft-Versus-Host-Model After Allogeneic Stem Cell Transplantations Unrelated to Red Cell Transfusion

Axel Nogai, Dr., Reinhard Ziebig, Dr., Martina U. Muckenthaler, Prof., PhD, Eckhard Thiel, Prof., Dr., Dr., h.c., Lutz Uharek, Prof., Dr., Michael Notter, Dr.

Blood (2010) 116 (21): 2048.

https://doi.org/10.1182/blood.V116.21.2048.2048

Published: 2010

Journal Articles

Frequency and Relevance of CD10 + CD19 + Hematogones after Allogeneic Stem Cell Transplantation.

Axel Nogai, Eckhard Thiel, Thomas Burmeister, Susanne Ganepola, Rita Lippoldt, Igor W. Blau, PD, Olga O. Blau, MD, PhD, Carola Tietze-Bürger, Lutz Uharek, Stefan Schwartz

Blood (2008) 112 (11): 3280.

https://doi.org/10.1182/blood.V112.11.3280.3280

Published: 2008

Journal Articles

A Shift in the Intestinal Microflora towards Pro-Inflammatory Bacteria and Signaling Via Toll-Like-Receptor 2 Triggers Early Onset of Graft-Versus-Host Disease.

Axel Nogai, Markus M. Heimesaat, Stefan Bereswill, PD, Eckhard Thiel, Ulf B. Goebel, Lutz Uharek

Blood (2007) 110 (11): 2171.

https://doi.org/10.1182/blood.V110.11.2171.2171

Published: 2007

Journal Articles

NK-Cell Recovery and Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation Using Either CD34 Selected Grafts and Adoptive NK-Cell Transfer or CD3/CD19 Depleted Grafts: Comparison of Two Strategies for NK Cell Based Immunotherapy.

Chiara Gentilini, MD, Matthias Haegele, Arne Muessig, MD, Axel Nogai, MD, Constanze Kliem, MD, Kristina Bartsch, MD, Nadezda Bazara, Wichard Vogel, MD, Christoph Faul, MD, Lothar Kanz, MD, Eckhard Thiel, Dietger W. Niederwieser, Lutz Uharek, Wolfgang A. Bethge, MD

Blood (2007) 110 (11): 2988.

https://doi.org/10.1182/blood.V110.11.2988.2988

Published: 2007

Journal Articles

Conditioning with Treosulfan and Cyclophosphamide without Application of Antibodies in MHC Mismatch Transplantations in Mice.

Axel Nogai, Marc Thiele, Markus M. Heimesaat, Eckhard Thiel, Ulf B. Goebel, Lutz Uharek

Blood (2006) 108 (11): 5159.

https://doi.org/10.1182/blood.V108.11.5159.5159

Published: 2006

NARROW

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Real-World Analysis of Teclistamab in 115 RRMM Patients from Germany

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma

Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant

Quantitative Detection of DNMT3A R882H Mutation in Course of Treatment of Acute Myeloid Leukemia Patients

SIRT3 Modulates Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells of Multiple Myeloma Patients

Cyclin D1 C.870G>a Polymorphism in Patients with Multiple Myeloma after Allogeneic Stem Cells Transplantation

Multiple Myeloma Cells Induce Mitochondrial Stress Response in Bone Marrow Mesenchymal Stromal Cells

Aberrant Expression Of miRNA and mRNA Of Cell Cycle and Adhesion-Related Genes In Bone Marrow Stroma Cells Derived From Patients With Multiple Myeloma

Successful Treatment of High-Risk and Refractory Acute Myeloid Leukemia with haploidentical Stem Cell Transplantation Plus NK cell therapy

Organ Siderosis In a Murine Graft-Versus-Host-Model After Allogeneic Stem Cell Transplantations Unrelated to Red Cell Transfusion

Frequency and Relevance of CD10 + CD19 + Hematogones after Allogeneic Stem Cell Transplantation.

A Shift in the Intestinal Microflora towards Pro-Inflammatory Bacteria and Signaling Via Toll-Like-Receptor 2 Triggers Early Onset of Graft-Versus-Host Disease.

NK-Cell Recovery and Immune Reconstitution after Haploidentical Hematopoietic Cell Transplantation Using Either CD34 Selected Grafts and Adoptive NK-Cell Transfer or CD3/CD19 Depleted Grafts: Comparison of Two Strategies for NK Cell Based Immunotherapy.

Conditioning with Treosulfan and Cyclophosphamide without Application of Antibodies in MHC Mismatch Transplantations in Mice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only